Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 03, 2021 08:00 ET | Source: Pharvaris N.V.

Pharvaris to Participate in Upcoming September Investor Conferences

ZUG, Switzerland, Sept. 03, 2021 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company focused on the development and commercialization of novel oral bradykinin-B2-receptor...
July 30, 2021 08:00 ET | Source: Pharvaris N.V.

Pharvaris Reports Second Quarter 2021 Financial Results and Provides Business Highlights

RAPIDe-1, Phase 2 on-demand study of PHVS416 for the treatment of HAE attacks expanding to US, expected to report data in 2022 CHAPTER-1, Phase 2 prophylactic study of PHVS416 for the prevention of...
July 09, 2021 18:10 ET | Source: Pharvaris N.V.

Pharvaris Presents Clinical Data on Oral PHA121 Supporting the Prophylactic Treatment of Hereditary Angioedema at the EAACI Annual Congress 2021

ZUG, Switzerland, July 10, 2021 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company focused on the development and commercialization of novel oral bradykinin-B2-receptor...
July 01, 2021 07:00 ET | Source: Pharvaris N.V.

Pharvaris to Present PHA121 Clinical Data for Oral Treatment of Hereditary Angioedema at the EAACI Annual Congress 2021

ZUG, Switzerland, July 01, 2021 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company focused on the development and commercialization of novel oral bradykinin-B2-receptor...
June 11, 2021 08:00 ET | Source: Pharvaris N.V.

Pharvaris Announces Annual Meeting of Shareholders

ZUG, Switzerland, June 11, 2021 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company focused on the development and commercialization of novel oral bradykinin-B2-receptor...
June 04, 2021 03:45 ET | Source: Pharvaris N.V.

Pharvaris Presents Pharmacokinetic and Pharmacodynamic Data for Oral PHA121, Under Development for the Treatment of HAE, at 12th C1 Inhibitor Deficiency and Angioedema Workshop

ZUG, Switzerland, June 04, 2021 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company focused on the development and commercialization of novel oral bradykinin-B2-receptor...
May 26, 2021 08:00 ET | Source: Pharvaris N.V.

Pharvaris Reports First Quarter 2021 Financial Results and Provides Business Highlights

RAPIDe-1, Phase 2 on-demand study of PHVS416 for the treatment of HAE attacks proceedingHAE CHAPTER-1, Phase 2 prophylactic study of PHVS416 for prevention of HAE attacks, on-track to initiate in...
May 12, 2021 07:00 ET | Source: Pharvaris N.V.

Pharvaris Appoints Wim Souverijns, Ph.D., as Chief Community Engagement & Commercial Officer

Industry veteran with deep commercial experience further strengthens leadership team as company advances development of multiple oral products for HAE patients ZUG, Switzerland, May 12, 2021 ...
April 29, 2021 16:15 ET | Source: Pharvaris N.V.

Pharvaris Reports Full Year 2020 Financial Results and Provides Business Highlights

RAPIDe-1 clinical trial enrolling, evaluating PHVS416 as an oral on-demand therapy for HAEOpen IND for the prophylactic evaluation of PHVS416Strong pre-IPO cash and cash equivalents balance of €98.6...
April 21, 2021 08:00 ET | Source: Pharvaris N.V.

Pharvaris Announces FDA Acceptance of IND Application for Prophylactic Treatment of HAE Using PHVS416

ZUG, Switzerland, April 21, 2021 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company focused on the discovery and development of novel oral bradykinin-B2-receptor antagonists for...